ProGen
ProGen is a biotech company focused on developing and commercializing innovative treatments for urothelial and specialty cancers.
Profile
Develop and commercialize treatments for urothelial and specialty cancers.
ProGen is a biotech company focused on developing and commercializing innovative treatments for urothelial and specialty cancers. Founded with a mission to address unmet medical needs in urology, the company has gained traction with its flagship product ZUSDURI™, the first FDA-approved medicine for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ProGen's product portfolio also includes JELMYTO, a treatment for low-grade upper tract urothelial carcinoma (LG-UTUC), and a pipeline of next-generation therapies like UGN-103 and UGN-104.
The company reported $29.2 million in Q1 2026 revenue from ZUSDURI, a 109% quarter-over-quarter growth, driven by broader adoption following the implementation of a permanent J Code in January 2026. ProGen's financial trajectory appears strong, with JELMYTO also showing steady growth at $21.7 million in Q1 2026, up 7% year-over-year. The company is advancing its pipeline, with UGN-103 on track for an NDA submission in late 2026. ProGen's recent momentum underscores its potential to become a leader in uro-oncology, though its reliance on a few key products and the competitive landscape pose risks.
Who buys this
- Urologists treating recurrent LG-IR-NMIBC
- Oncologists specializing in urothelial cancers
- Hospital and community healthcare providers
- Patients with low-grade upper tract urothelial carcinoma
- Biopharmaceutical partners for pipeline development
Strengths and what to watch
Strengths
- First FDA-approved medicine for recurrent LG-IR-NMIBC (ZUSDURI™)
- Strong revenue growth driven by permanent J Code adoption
- Advancing pipeline with UGN-103 and UGN-104
Watch for
- Dependence on ZUSDURI™ for revenue growth
- Competition in the urothelial cancer treatment space
- Pipeline delays or regulatory hurdles for UGN-103 and UGN-104
Recent moves
Key Information
- Founded
- 2008
Frequently Asked Questions
What does ProGen specialize in?
ProGen is a biotech company focused on developing and commercializing treatments for urothelial and specialty cancers. Its flagship products include ZUSDURI™ for recurrent low-grade bladder cancer and JELMYTO for low-grade upper tract urothelial carcinoma.
What is ZUSDURI™ used for?
ZUSDURI™ is the first FDA-approved medicine for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). It has driven significant revenue growth for ProGen, with $29.2 million reported in Q1 2026.
How has ProGen performed financially in 2026?
ProGen reported strong financial growth in Q1 2026, with ZUSDURI™ revenue reaching $29.2 million, a 109% quarter-over-quarter increase. JELMYTO also grew to $21.7 million, up 7% year-over-year, driven by broader adoption and permanent J Code implementation.
What is ProGen's pipeline for future treatments?
ProGen is advancing its pipeline with UGN-103 and UGN-104. UGN-103 is on track for an NDA submission in late 2026, aiming to expand the company’s offerings in urothelial cancer treatments.
Who are ProGen's primary customers?
ProGen’s primary customers include urologists treating recurrent bladder cancer, oncologists specializing in urothelial cancers, hospital and community healthcare providers, patients with low-grade upper tract urothelial carcinoma, and biopharmaceutical partners for pipeline development.
What are the risks facing ProGen?
ProGen faces risks such as dependence on ZUSDURI™ for revenue growth, competition in the urothelial cancer treatment space, and potential pipeline delays or regulatory hurdles for UGN-103 and UGN-104.
Sources
- investors.urogen.com — Q1 2026 financial results and ZUSDURI revenue growth
- techcrunch.com — General tech industry context
- userevidence.com — Market trends in customer evidence
- www.bloomberg.com — General business and financial context